User:Mr. Ibrahem/Pralatrexate
 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Folotyn |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Routes of administration | Intravenous |
| Drug class | Dihydrofolate reductase inhibitor[1] |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C23H23N7O5 |
| Molar mass | 477.481 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Pralatrexate, sold under the brand name Folotyn, is a medication to treat peripheral T-cell lymphoma (PTCL).[1] It is used when other treatments have failed.[1] It is given by injection into a vein.[1]
Common side effects include inflammation of the mouth, low platelets, nausea, and tiredness.[1] Other side effects may include rash, tumor lysis syndrome, liver problems, and bone marrow suppression.[1] Use in pregnancy may harm the baby.[1] It is a dihydrofolate reductase inhibitor.[1]
Pralatrexate was approved for medical use in the United States in 2009.[1] Its approval was refused in Europe in 2012 due to insufficient evidence of benefit.[2] In the United States 60 mg of medication costs about 18,000 USD.[3]
References[edit]
- ^ a b c d e f g h i j k l "Folotyn- pralatrexate injection". DailyMed. 28 May 2020. Archived from the original on 30 March 2021. Retrieved 21 October 2020.
- ^ "Folotyn". Archived from the original on 26 November 2020. Retrieved 29 October 2021.
- ^ "Pralatrexate Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 29 October 2021.